Copyright
©The Author(s) 2021.
World J Gastrointest Oncol. Dec 15, 2021; 13(12): 2129-2148
Published online Dec 15, 2021. doi: 10.4251/wjgo.v13.i12.2129
Published online Dec 15, 2021. doi: 10.4251/wjgo.v13.i12.2129
Table 1 Relationship between BRAFV600E mutation and clinicopathological parameters in colorectal cancer
| Variable | Cases (%) | BRAFV600E mutation | P value | |
| Yes (%) | No (%) | |||
| Gender | ||||
| Male | 18 (60) | 6 (60) | 12 (60) | 0.326 |
| Female | 12 (40) | 4 (40) | 8 (40) | |
| Age (yr) | ||||
| ≥ 65 | 10 (33.3) | 4 (40) | 6 (30) | 0.440 |
| < 65 | 20 (66.7) | 6 (60) | 14 (70) | |
| Location | ||||
| Right colon | 9 (30) | 2 (20) | 7 (35) | 0.345 |
| Left colon | 9 (30) | 5 (50) | 4 (20) | |
| Rectum | 12 (40) | 3 (30) | 9 (45) | |
| Mucous tissue | ||||
| Positive | 6 (20) | 1 (10) | 5 (25) | 0.326 |
| Negative | 24 (80) | 9 (90) | 15 (75) | |
| Differentiated degree | ||||
| High/moderate differentiation | 20 (66.7) | 3 (30) | 17 (85) | 0.005a |
| Poor differentiation | 10 (33.3) | 7 (70) | 3 (15) | |
| T stage | ||||
| T2 | 4 (13.3) | 0 | 4 (20) | 0.211 |
| T3 | 3 (10) | 2 (20) | 1 (5) | |
| T4 | 23 (76.7) | 8 (80) | 15 (75) | |
| TNM stage | ||||
| I + II | 13 (43.3) | 2 (20) | 11 (55) | 0.074 |
| III + IV | 17 (56.7) | 8 (80) | 9 (45) | |
| Lymph node | ||||
| Positive | 17 (56.7) | 8 (80) | 9 (45) | 0.074 |
| Negative | 13 (43.3) | 2 (20) | 11 (55) | |
| Nerve invasion | ||||
| Positive | 7 (23.3) | 4 (40) | 3 (15) | 0.143 |
| Negative | 23 (76.7) | 6 (60) | 17 (85) | |
| Vessel carcinoma embolus | ||||
| Positive | 3 (10) | 1 (10) | 2 (10) | 0.652 |
| Negative | 27 (90) | 9 (90) | 18 (90) | |
| CA19-9 (U/mL) | ||||
| High | 12 (40) | 7 (70) | 5 (25) | 0.024a |
| Normal | 18 (60) | 3 (30) | 15 (75) | |
| CEA (ng/mL) | ||||
| High | 11 (36.7) | 3 (30) | 8 (40) | 0.452 |
| Normal | 19 (63.3) | 7 (70) | 12 (60) | |
| PLT count (× 109/L) | ||||
| High | 12 (40) | 5 (50) | 7 (35) | 0.344 |
| Normal | 18 (60) | 5 (50) | 13 (65) | |
Table 2 Relationship between BRAFV600E mutation and microvascular density/microlymphatic vessel density in colorectal cancer
| BRAFV600E mutation | MVD | MLVD | ||
| mean ± SD | P value | mean ± SD | P value | |
| + | 38.53 ± 17.11 | 0.030 | 9.67 ± 5.63 | 0.0001 |
| - | 27.54 ± 9.54 | 3.81 ± 2.06 | ||
Table 3 Relationship between BRAFV600E mutation and tumor-associated macrophages in colorectal cancer
| BRAFV600E mutation | CD68+ macrophage | CD163+ M2 macrophage | ||
| mean ± SD | P value | mean ± SD | P value | |
| + | 18.43 ± 13.53 | 0.664 | 8.33 ± 5.93 | 0.040 |
| - | 20.96 ± 15.34 | 3.67 ± 3.02 | ||
Table 4 Relationship between BRAFV600E mutation and cancer-associated fibroblasts in colorectal cancer
| BRAFV600E mutation | CAFs | P value | |
| Low expression (cases) | High expression (cases) | ||
| + | 2 | 8 | 1 |
| - | 3 | 17 | |
- Citation: Zhi J, Jia XJ, Yan J, Wang HC, Feng B, Xing HY, Jia YT. BRAFV600E mutant colorectal cancer cells mediate local immunosuppressive microenvironment through exosomal long noncoding RNAs. World J Gastrointest Oncol 2021; 13(12): 2129-2148
- URL: https://www.wjgnet.com/1948-5204/full/v13/i12/2129.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v13.i12.2129
